<- Back to digest

Journal of Pediatric Orthopaedics - 2026-10-12 - Journal Article

Trisomy 21 and Patellar Femoral Instability in a Pediatric Population: Results From 53,800 Patients.

Magoline JA, Yoder RG, Morscher MA, Riley PM, Bono KT, Polousky JD, Kaelber DC, Tysklind RG

database studyLOE IIIn = 53,800 T21 patients; 347 matched pairs for surgical comparisonAnnual prevalence tracked 2017–2024; time-to-surgery via Kaplan-Meier (duration not explicitly stated as mean follow-up)

Topics

pediatrics
PMID: 42860872DOI: 10.1097/BPO.0000000000003499View on PubMed ->

Key Takeaway

Among 53,800 pediatric T21 patients, PFI prevalence was 0.81% in 2024—lower than prior reports—but T21 patients with PFI underwent surgery at 1.76× the rate of matched non-T21 peers (18.7% vs. 10.7%).

Summary Depth

Choose how much analysis to show on this article page.

Summary

This retrospective TriNetX database study quantified PFI prevalence in pediatric T21 patients and compared surgical intervention rates against 1:1 propensity-score-matched non-T21 PFI patients. Annual PFI prevalence in T21 rose from 0.54% (2017) to 0.81% (2024), with females exceeding males (0.97% vs. 0.67%). T21 patients underwent patellofemoral reconstruction at nearly twice the rate of matched controls (18.7% vs. 10.7%; RR 1.76, 95% CI 1.21–2.56), though time-to-surgery did not differ significantly (log-rank P=0.054).

Key Limitation

CPT-code-based surgical identification cannot differentiate procedure type (e.g., MPFL reconstruction vs. tibial tubercle osteotomy vs. soft-tissue realignment), preventing assessment of whether T21-specific anatomy drives both the higher surgical rate and potentially different procedure selection.

Original Abstract

BACKGROUND

Patellofemoral instability (PFI) commonly occurs in pediatric patients with Trisomy 21 (T21). Reported prevalence ranges from 1.5% to over 20%. This study establishes incidence and prevalence among tens of thousands of T21 patients and compares rates of surgical intervention with a matched non-T21 cohort.

METHODS

We conducted a retrospective analysis using the TriNetX Research USA Minimal Date Shift network, which includes de-identified electronic health records from 59 healthcare organizations. Patients with T21 and PFI (ICD-10 code S83.00 or M22.1) diagnosed at or before age 19 were included. We evaluated rates of surgical intervention for PFI using CPT codes for patellofemoral reconstruction procedures in T21 patients and compared them to an age, sex, race, and ethnicity-matched non-T21 patients with PFI. The annual point prevalence of PFI in Down syndrome patients was also calculated in a separate cohort from 2017 to 2024.

RESULTS

Among 53,800 patients with T21, the annual prevalence of PFI increased from 0.54% in 2017 to 0.81% in 2024. Females exhibited a higher prevalence than males (0.97% vs. 0.67% in 2024). The mean age at initial PFI diagnosis among patients with T21 was 11.1±4.7 years. Following 1:1 propensity-score matching, 18.7% (65/347) of patients with T21 and PFI underwent surgical treatment compared with 10.7% (37/347) of matched patients without T21 (RR, 1.76; 95% CI, 1.21-2.56). Kaplan-Meier analysis demonstrated no statistically significant difference in time from PFI diagnosis to surgery between matched cohorts (log-rank P=0.054; HR, 1.49; 95% CI, 0.99-2.23).

CONCLUSIONS

This is the first prevalence analysis of PFI in tens of thousands of children with T21. The findings reveal lower prevalence than previously reported, but a higher likelihood of surgical treatment compared with non-T21 peers. These results underscore the need to better understand how the current treatment strategies for PFI can affect this population and stress the importance of longitudinal monitoring of PFI in T21 patients.

LEVEL OF EVIDENCE

Level III.